AMSTERDAM, Netherlands, June 3, 2015 (GLOBE NEWSWIRE) -- Today at EyeforPharma, Real World Evidence in Amsterdam, the Netherlands, Zephyr Health, the insights-as-a-service company for Life Sciences, announced the launch of its Real World data initiative using statistics on diabetes in England as the basis for demonstrating how patient outcomes can add value to commercial strategies.
Real world data is essential to gain competitive advantage for the launch of a biopharmaceutical or medical device product. Until today, creating actionable insights from disparate healthcare sources has been a challenge. Zephyr Health's solutions create novel insights by contextualizing and linking data from disconnected sources such as patient density, prescription and referral patterns, readmissions, population health and more for an evidence-based approach to a product lifecycle management from strategy to clinical development to market adoption.
"Life Science companies need to make better use of the insights that real world data can provide in order to improve market access, sales and marketing growth strategies," said William King, founder and CEO, Zephyr Health. "Using this very specific disease area and geography (e.g. diabetes in England) as a case study, we are demonstrating the power of our unique solution that takes a fact-based approach to targeting critical market needs and opportunities."
With this initiative, Zephyr Health is providing leaders from biopharmaceutical and medical device companies with access to a special edition of its powerful insights solution, pre-loaded with diabetes incidence, demographics, and other market data on England. Life science marketing and commercial teams will be able to experience first hand how increased insights into market and customer potential can improve and accelerate sales and marketing activities.
Additionally, when combined with 3rd party vendor CRM or ERP system data, real world healthcare insights give commercial teams confidence that their new and existing therapies will reach the right physicians and patients rapidly.
Zephyr Health customers, including Fortune 100 biopharmaceutical and medical device companies, are using the company's proprietary algorithms and data science to accelerate product performance - from inception to post-launch commercial campaigns - harnessing big-data powered insights delivered via the company's business-user friendly enterprise applications. Zephyr Health integrates thousands of global data sources on one easy-to-use insights platform, providing unparalleled business insights pre-built for life sciences functional leaders involved in product lifecycle management.
Connect with Zephyr Health:
- Follow @zephyrhealth on Twitter
- Connect with Zephyr Health on LinkedIn
- Want to try it out for yourself? Sign up for access to our Real World Data, Diabetes England solution: http://go.zephyrhealth.com/diabetes-real-world-evidence
- For more info: https://zephyrhealth.com/real-world-evidence/
About Zephyr Health
Founded in 2011 by William King, Zephyr Health is the leading insights-as-a-service company harnessing the power of Big Data for precise and confident product lifecycle performance for biopharmaceutical and medical device companies. From clinical trials to market strategy and sales, our solutions connect data from thousands of sources across the global healthcare ecosystem to produce deep, predictive insights that our customers can use to better connect their therapies to the people who need them the most. Zephyr Health is a privately held company headquartered in San Francisco with offices in London, UK and Pune, India. Zephyr Health is venture backed by Kleiner Perkins Caufield & Byers and Icon Ventures. For more information, please visit: www.zephyrhealth.com.